PPD

JDRF Names PPD Preferred Provider

Monday, October 20, 2008 09:00 AM

The Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of type 1 diabetes research, has teamed up with global contract research organization (CRO) PPD in a unique partnership designed to improve clinical research for type 1 diabetes.

More... »

CWWeekly June 30th 2008 Issue

Monday, July 7, 2008 10:32 AM

Top News

More... »

eClinical Round-Up

Tuesday, July 1, 2008 09:47 AM

During the DIA 2008 Annual Meeting held in Boston, Phase Forward announced it formed an alliance with AG Mednet to streamline the process of transporting medical imaging, such as MRIs, CAT scans and ultrasounds. The alliance calls for the combining of InForm, Phase Forward’s trial management system, and AG Mednet’s imaging transport network for better tracking and management of patient images in real time from sites to imaging experts. “Clinical trial sponsors need a way to transport patient images more quickly and efficiently for less cost, and a real-time capability to track and manage these images,” said Martin Young Phase Forward’s vice president of corporate development and marketing.

More... »

In India, A Pairing Born Of Necessity

Monday, October 9, 2006 11:56 AM

India’s clinical research market entered a new era in January 2005 with the signing of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. TRIPS requires the country to honor all product patents issued after 1995.

More... »

A Stock Split Can Make You Forget

Wednesday, February 15, 2006 11:06 AM

PPD's two-for-one stock split is good news for the top global clinical  research organizations. Investors attracted to the sector by the  company's split announcement Feb. 8 can focus on PPD and other top CROs  rather than the sideshow embattled SFBC has become. When new investors look at top CROs such as PPD, Quintiles , PRA, ICON, Parexel and Covance, they will see the pharmaceutical outsourcing industry  ready to consolidate around a handful or so of these companies.These  global CROs have a big advantage over the estimated 1,000 other small  CROs throughout the world. They have international infrastructure in  place to conduct complex clinical trials in thousands of patients at  sites across multiple countries.That global presence is not easy to  build and represents a barrier to entry for small CROs trying to roll  up into a global player.

More... »

What's In A Name? A Fresh Start, Maybe

Friday, February 3, 2006 02:09 PM

A new CEO and a change of scenery are good first steps to righting the ship at SFBC. A new name could also do the embattled contract research organization some good. Something like, say, PharmaNet? Two weeks ago Jeffrey McMullen assumed the role of CEO. He joined SFBC as part of the company’s December 2004 acquisition of CRO PharmaNet for $245 million in cash. By our measures, the PharmaNet name has a lot of positive brand equity. It has been a top performer in the Thomson CenterWatch Survey of Investigative Sites in the US in 2005 and 2003. It was also top-rated in Europe in 2004. That’s high praise from our survey respondents – principal investigators and study coordinators – who are on the front lines of clinical research.

More... »